STAT1-independent inhibition of cyclooxygenase-2 expression by IFNγ; a common pathway of IFNγ-mediated gene repression but not gene activation

Oncogene

Volumn 26, Issue 14, 2007, Pages 2071-2081

  Klampfer, L ^a   Huang, J ^a   Kaler, P ^a   Sasazuki, T ^b   Shirasawa, S ^b   Augenlicht, L ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Colon cancer; COX 2; IFN; JAK; STAT1

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; JANUS KINASE; RAS PROTEIN; STAT1 PROTEIN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE REPRESSION; GENE SILENCING; GENOME ANALYSIS; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

CELLS, CULTURED; CYCLOOXYGENASE 2; DOWN-REGULATION; GENE EXPRESSION; GENE SILENCING; HUMANS; INTERFERON TYPE II; INTESTINAL MUCOSA; JANUS KINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BIOSYNTHESIS; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS);

EID: 34047191343     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210015     Document Type: Article

References (50)

1. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J et al. (1998). Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 47: 113-120.
2. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M et al. (2003). Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 63: 728-734.
3. Battcock SM, Collier TW, Zu D, Hirasawa K. (2006). Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. J Virol 80: 4422-4430.
4. Biasco G, Rossini FP, Hakim R, Brandi G, Di Battista M, Di Febo G et al. (2002). Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme. Dig Liver Dis 34: 339-342.
5. Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN et al. (2004). SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 166: 37-47.
6. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. (2000). Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 191: 2131-2144.
7. Brown JR, DuBois RN. (2005). COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855.
8. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM et al. (2003). Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171: 6164-6172.
9. Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL et al. (2002). Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 8: 2067-2072.
10. Deb A, Haque SJ, Mogensen T, Silverman RH, Williams BR. (2001). RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol 166: 6170-6180.
11. Durbin JE, Hackenmiller R, Simon MC, Levy DE. (1996). Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450.
12. Dvorak HF. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650-1659.
13. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188.
14. Gil MP, Bohn E, O'Guin AK, Ramana CV, Levine B, Stark GR et al. (2001). Biologic consequences of Stat1-independent IFN signaling. Proc Natl Acad Sci USA 98: 6680-6685.
15. Gupta RA, Dubois RN. (2001). Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1: 11-21.
16. Guy-Grand D, DiSanto JP, Henchoz P, Malassis-Seris M, Vassalli P. (1998). Small bowel enteropathy: role of intraepithelial lymphocytes and of cytokines (IL-12, IFN-gamma, TNF) in the induction of epithelial cell death and renewal. Eur J Immunol 28: 730-744.
17. Hanna N, Bonifacio L, Reddy P, Hanna I, Weinberger B, Murphy S et al. (2004). IFN-gamma-mediated inhibition of COX-2 expression in the placenta from term and preterm labor pregnancies. Am J Reprod Immunol 51: 311-318.
18. Higaki S, Akazawa A, Nakamura H, Yanai H, Yoshida T, Okita K. (1999). Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol 14: 709-714.
19. Hu J, Roy SK, Shapiro PS, Rodig SR, Reddy SP, Platanias LC et al. (2001). ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. J Biol Chem 276: 287-297.
20. Janabi N, Jensen PN, Major EO. (2004). Differential effects of interferon-gamma on the expression of cyclooxygenase-2 in high-grade human gliomas versus primary astrocytes. J Neuroimmunol 156: 113-122.
21. Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM et al. (2003). MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22: 8031-8041.
22. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ et al. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95: 7556-7561.
23. Klampfer L, Huang J, Corner G, Mariadason J, Arango D, Sasazuki T et al. (2003a). Oncogenic k-ras inhibits the expression of IFN-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 278: 46278-46287.
24. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. (2003b). Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol Cancer Res 1: 855-862.
25. Klampfer L, Huang J, Swaby LA, Augenlicht L. (2004). Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 279: 30358-30368.
26. Kowanetz M, Valcourt U, Bergstrom R, Heldin CH, Moustakas A. (2004). Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 24: 4241-4254.
27. Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A et al. (2000). Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 1: 7-14.
28. Levy DE, Darnell Jr JE. (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
29. Lindner DJ. (2002). Interferons as antiangiogenic agents. Curr Oncol Rep 4: 510-514.
30. Mariadason JM, Nicholas C, L'Italien KE, Zhuang M, Smartt HJ, Heerdt BG et al. (2005). Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology 128: 1081-1088.
31. Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ et al. (1999). Regulation of cyclooxygenase-2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J Biol Chem 274: 29138-29148.
32. Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS et al. (1996). Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
33. Muller-Tidow C, Diederichs S, Thomas M, Serve H. (2004). Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. Lung Cancer 45(Suppl 2): S145-S150.
34. Navarro A, Anand-Apte B, Tanabe Y, Feldman G, Larner AC. (2003). A PI-3 kinase-dependent, Stat1-independent signaling pathway regulates interferon-stimulated monocyte adhesion. J Leukocyte Biol 73: 540-545.
35. Perk J, Iavarone A, Benezra R. (2005). Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5: 603-614.
36. Qing Y, Stark GR. (2004). Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 279: 41679-41685.
37. Ramana CV, Gil MP, Han Y, Ransohoff RM, Schreiber RD, Stark GR. (2001). Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci USA 98: 6674-6679.
38. Ramana CV, Gil MP, Schreiber RD, Stark GR. (2002). Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23: 96-101.
39. Ramana CV, Grammatikakis N, Chernov M, Nguyen H, Goh KC, Williams BR et al. (2000). Regulation of c-myc expression by IFN-gamma through Stat1-dependent and - independent pathways. EMBO J 19: 263-272.
40. Ramsauer K, Sadzak I, Porras A, Pilz A, Nebreda AR, Decker T et al. (2002). p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc Natl Acad Sci USA 99: 12859-12864.
41. Schindler C, Shuai K, Prezioso VR, Darnell Jr JE. (1992). Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 257: 809-813.
42. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. (2001). IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
43. Sharma B, Iozzo RV. (1998). Transcriptional silencing of perlecan gene expression by interferon-gamma. J Biol Chem 273: 4642-4646.
44. Sheng H, Shao J, Dubois RN. (2001). K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B1. Cancer Res 61: 2670-2675.
45. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88.
46. Shuai K, Schindler C, Prezioso VR, Darnell Jr JE. (1992). Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 258: 1808-1812.
47. Vila-del Sol V, Fresno M. (2005). Involvement of TNF and NF-kappa B in the transcriptional control of cyclooxygenase-2 expression by IFN-gamma in macrophages. J Immunol 174: 2825-2833.
48. Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell Jr JE. (1996). DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15: 5616-5626.
49. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND et al. (1997). Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272: 28779-28785.
50. Wright KL, Weaver SA, Patel K, Coopman K, Feeney M, Kolios G et al. (2004). Differential regulation of prostaglandin E biosynthesis by interferon-gamma in colonic epithelial cells. Br J Pharmacol 141: 1091-1097.